Lankenau Institute for Medical Research (LIMR)
Lankenau Institute for Medical Research (LIMR) is a leading research institute dedicated to studying and developing remedies for cancer, cardiovascular, autoimmune, gastrointestinal, and other diseases. LIMR is at the forefront of the immunotherapy revolution in healthcare, driven by the principle that hope in medicine springs from research. The institute combines a unique mix of academic culture and entrepreneurial spirit, known as the ACAPRENEURIAL™ strategy, to integrate non-profit research with for-profit biotechnology initiatives, fostering a collaborative environment for translating preclinical discoveries into clinical applications.
Lankenau Institute for Medical Research (LIMR)
What We Do
A small molecule drug in late-stage clinical development targeting the IDO pathway, developed in collaboration with NewLink Genetics Corp. and LIMR.
An FDA-authorized product that tests synovial fluid for periprosthetic joint infection, developed by Carl Deirmengian, MD, at LIMR.
A blood-based assay developed by LIMR to predict which cancer patients will experience delayed-onset nausea after chemotherapy.
A test developed by LIMR to determine if small triple-negative breast cancers are aggressive and best treated with chemotherapy.
LIMR scientists have developed a unique patient-derived huMab that recognizes a common structural feature of all mammalian and bacterial amyloid proteins, offering potential applications in Alzheimer's disease therapy.
LIMR conducts basic, preclinical, and clinical cancer research, focusing on disease modifiers that affect inflammation and immunity. The institute is renowned for its expertise in tumor microenvironments and immune responses, contributing to the immunotherapy revolution.
Application Area
Show More (5)Key People
News & Updates
LIMR scientists find evidence that Vitamin D increases the lung lining’s ability to block infection.
LIMR is the first clinical trial site in the United States for a novel investigational therapy aimed at treating advanced and metastatic prostate cancer.
A U.S. provisional patent has been filed for the huMab that includes the IgG sequences, offering potential applications in Alzheimer's disease therapy.